The Long-term Safety Trial was approved to be conducted by China National Medical Products Administration (NMPA) on 18 April 2023
Planned investment of approximately USD 90 million to build a state-of-the-art Sandoz Biosimilar Technical Development Center in Ljubljana, Slovenia by 2026
Evonik specializes in mid- to large-scale, later clinical phase HPAPIs
SMPA's diverse portfolio includes six marketed products and a robust pipeline of early- to late-stage assets
Especially valuable for young patients with multiple blocks & underlying conditions that may render angioplasty procedures with drug-eluting stents ineffective
Exothera will manufacture Meissa’s MV-012-968 vaccine candidate under CGMP regulations to supply Phase 2 clinical trials
Antimicrobial Resistance (AMR) poses a significant threat to global healthcare systems and patient safety
The investment is part of Croda’s continuing commitment to develop high performance pharmaceutical ingredients and technologies for life sciences.
This trial is a multi-national, phase 2/3, open-label, randomized, controlled clinical study of utidelone injectable
Collaboration to accelerate and de-risk clinical development of Nanopharmaceutics CNS portfolio
Subscribe To Our Newsletter & Stay Updated
